Personalized Oxycodone Dosing: Using Pharmacogenetic Testing and Clinical Pharmacokinetics to Reduce Toxicity Risk and Increase Effectiveness
Authors:
Open Access
- 1 May 2014
- journal article
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 15 (5) , 723-725
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Opioids and their receptors: Are we there yet?Neuropharmacology, 2014
- Mu Opioids and Their Receptors: Evolution of a ConceptPharmacological Reviews, 2013
- Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patientsBlood, 2013
- Simultaneous Pharmacogenetics-Based Population Pharmacokinetic Analysis of Darunavir and Ritonavir in HIV-Infected PatientsClinical Pharmacokinetics, 2013
- Association between UGT1A1*28 Polymorphisms and Clinical Outcomes of Irinotecan-Based Chemotherapies in Colorectal Cancer: A Meta-Analysis in CaucasiansPLOS ONE, 2013
- XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studiesJournal of Zhejiang University-SCIENCE B, 2012
- A Genotypic Test for HIV-1 Tropism Combining Sanger Sequencing with Ultradeep Sequencing Predicts Virologic Response in Treatment-Experienced PatientsPLOS ONE, 2012
- Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogeneticsExpert Opinion on Drug Metabolism & Toxicology, 2011
- Codeine, Ultrarapid-Metabolism Genotype, and Postoperative DeathNew England Journal of Medicine, 2009
- Impact of CYP2D6 Genetic Polymorphism on Tramadol Pharmacokinetics and PharmacodynamicsMolecular Diagnosis & Therapy, 2007